Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm, phase I study to determine the safety, PK characteristics
and anti-inflammatory effects of the NK-R1 coadministered with ritonavir-containing
antiretroviral therapy in individuals with well-controlled viral replication.
Our hypothesis is that Aprepitant will be safe, well tolerated, and will have
anti-inflammatory properties when administered concomitantly with the protease inhibitor
ritonavir.